Ocular Therapeut Stock Price, News & Analysis

Ocular Therapeutix (NASDAQ:OCUL) has announced the dosing of its first patient in a real-world study in China, evaluating the safety and efficacy of DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for treating ocular inflammation and pain post-cataract surgery. This trial aims to enroll about 120 patients and assess key endpoints at Days 8 and 14. Ocular entered a licensing agreement with AffaMed Therapeutics in 2020, receiving an upfront payment of $12 million and the potential for up to $91 million in milestone payments. The ophthalmology market in China is valued at $5 billion.

Ocular Therapeutix, Inc. (Nasdaq: OCUL) announced its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The management team will also host virtual investor meetings during the event. A pre-recorded presentation will be available from 7:00 AM ET on January 10 and can be accessed on the Company's investors section of its website, with a replay available for 90 days. Ocular Therapeutix focuses on innovative therapies for eye conditions.

Ocular Therapeutix announced positive topline results from its Phase 2 clinical trial of OTX-DED, a dexamethasone insert for treating dry eye disease. The trial achieved its primary endpoint, showing significant improvement in bulbar conjunctival hyperemia compared to a vehicle insert, with p-values of 0.004 and 0.028 for the 0.2 mg and 0.3 mg formulations, respectively. The studied insert was well tolerated, with no ocular serious adverse events reported. A conference call to discuss the findings is scheduled for 8:00 a.m. ET.

Ocular Therapeutix, Inc. (Nasdaq: OCUL) will participate in two upcoming healthcare conferences: the Jefferies London Healthcare Conference on November 18, 2021, with on-demand access to a pre-recorded fireside chat, and the Piper Sandler 33rd Annual Healthcare Conference starting November 22, 2021. Management will have virtual investor meetings available. Interested investors can view the presentations through the company's website.

Ocular Therapeutix announced that the U.S. Court of Appeals for the Federal Circuit upheld the Patent Trial and Appeal Board's (PTAB) ruling declaring Mati Therapeutics’ patent invalid. This ruling affects the patent related to dexamethasone drug delivery systems, previously claimed to be infringed by Ocular's product, DEXTENZA®. CEO Antony Mattessich expressed satisfaction with the ruling, reinforcing Ocular's commitment to protecting its products. The company holds multiple patents for DEXTENZA, expiring between 2030 and 2040, and continues to believe in the invalidity of any further claims from Mati.

Ocular Therapeutix reported third-quarter results with net product revenue of $12.2 million, a 107% increase year-over-year. DEXTENZA sales reached $11.9 million, up 120% from Q3 2020. The FDA approved a supplemental NDA for DEXTENZA to treat allergic conjunctivitis, enhancing its market position. Medicare confirmed separate payments for DEXTENZA in outpatient settings through 2022, positioning the product for future growth. However, the Phase 2 trial for OTX-CSI showed no significant efficacy, which may impact investor sentiment.

Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) confirmed separate payment for DEXTENZA in 2022 and beyond, enhancing accessibility for patients. The recent OPPS final rule supports DEXTENZA's eligibility as a non-opioid surgical supply. Additionally, the new Category I CPT Code 68841 for DEXTENZA's insertion establishes standard payments of $37.29 in physician offices and $31.58 in outpatient settings, broadening reimbursement coverage. These developments signify important financial and operational milestones for the company.

Ocular Therapeutix (NASDAQ:OCUL) announced key scientific presentations at the American Academy of Optometry Annual Meeting 2021 in Boston, MA, from November 3-6. The company highlighted DEXTENZA® for treating ocular inflammation, pain, and itching associated with allergic conjunctivitis. Presentations include analyses of a hydrogel-based dexamethasone insert and comparisons of treatment methods for conditions like keratoconus and dry eye. All presentations will be available on the company’s website starting November 5.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) will report its third quarter financial results on November 8, 2021, after market close. A live conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the webcast on the company's website or via phone. The company specializes in innovative ocular therapies and is advancing products like DEXTENZA®, while also developing drugs for conditions like wet AMD and glaucoma.